Corinne Faivre-Finn, Professor of Thoracic Radiation Oncology at The University of Manchester, shared a post on LinkedIn:
“It was a privilege to speak about drug-radiotherapy combinations and our experience with the CONCORDE platform during the European Society for Radiotherapy and Oncology (ESTRO) session at ELCC 2026:
‘Harnessing the synergy of radiotherapy and systemic therapy combinations in lung cancer.’
I was delighted to share the stage with outstanding colleagues covering complementary and forward-looking perspectives:
- Radiotherapy and systemic therapy combinations in stage III NSCLC: current and future standards of care, with Jessica Menis
- Emerging role of targeted therapies combined with radiotherapy in inoperable stage I–III NSCLC, with Ernest Nadal
- What is the optimal role of radiotherapy in the immunotherapy era in patients with small cell lung cancer? , with Gerry Hanna
- The challenge of testing novel systemic therapy with radiotherapy in NSCLC: lessons learnt so far from the CONCORDE study
I highlighted how platform trials, thoughtful trial design, and close multidisciplinary collaboration are essential to safely and efficiently evaluate novel drug-RT combinations.
Grateful to the organisers and co-speakers for a stimulating session.”
Title: CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
Authors: Gerard M. Walls, Jamie B. Oughton, Anthony J. Chalmers, Sarah Brown, Fiona Collinson, Martin D. Forster, Kevin N. Franks, Alexandra Gilbert, Gerard G. Hanna, Nicola Hannaway, Stephen Harrow, Tom Haswell, Crispin T. Hiley, Samantha Hinsley, Matthew Krebs, Geraldine Murden, Rachel Phillip, Anderson J. Ryan, Ahmed Salem, David Sebag-Montefiore, Paul Shaw, Chris J. Twelves, Katrina Walker, Robin J. Young, Corinne Faivre-Finn, Alastair Greystoke
Read the Full Article.
What Are the Most Important Lung Cancer Trials to Watch at ELCC 2026?